Targeted Long Acting Therapy intended to clear the HIV virus.
We are the Targeted Long-acting Combination Anti-Retroviral Therapy (TLC-ART) program, located within the Department of Pharmaceutics at the University of Washington. We are scientists and physicians working toward developing a long acting and effective treatment to improve patient compliance and therapeutic outcomes in the treatment of HIV. Our hope is to maximally suppress HIV and potentially contribute to a cure for AIDS.
In the past, HIV treatments involved a complicated regimen of certain drugs taken at specific times. Our goal is to launch a 3-drug combination called TLC-ART. TLC-ART, unlike other HIV treatments, TLC-ART will only need to be taken once a month.
Our researchers were the first to document pharmacological drug deficiencies with HIV oral treatment. This has been linked to residual HIV in tissues. The TLC-ART program, with its 11 projects, intends to overcome pharmacological drug deficiency by developing a novel formulation of a combination of antiretroviral agents. TLC-ART is a publicly funded, National Institutes of Health (NIH) supported program with contributions from multiple institutions.
We welcome your input, research support, participation and donations by either making a gift or donating directly to our faculty or students.